OCT 02, 2018 09:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Comprehensive Enumeration of Immune Cells in Solid Tumors

SPONSORED BY: IONpath
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Pincipal Investigator, The Stanford Blood Center
    Biography
      Mike's academic background spans across the fields of physics, biochemistry, electrical engineering, and medicine. During his residency he became interested in developing novel methods for immunohistochemical multiplexing using mass spectrometry leading to the development of MIBI during his postdoctoral work in the Nolan lab at Stanford University. Mike is now interested in optimizing MIBI and other mass reporter-based technologies further with the goal of identifying new transcriptional and translational signatures in solid tissue malignancies, and in allergic and other immunological disorders, that can be used to improve clinical diagnosis and treatment.

    Abstract:

    DATE: October 2, 2018
    TIME: 9:00AM PDT

    Understanding the role of distinct cellular phenotypes in tissue function, development, and pathogenesis requires tools that can rapidly and consistently quantify the expression of multiple proteins while preserving spatial information. Multiplexed Ion Beam Imaging by Time-Of-Flight  (MIBI-TOF) detects elements from hydrogen to uranium, permitting simultaneous measurement of up to 42 labeled antibodies along with histochemical stains and native biological elements.  We recently used this capability to analyze infiltrating immune cell populations in archival formalin-fixed paraffin embedded (FFPE) tissue sections from 42 triple negative breast cancer patients.  Spatial enrichment analysis showed immune mixed and compartmentalized tumors, coinciding with expression of PD1, PD-L1 and IDO in a cell-type and location-specific manner. Ordered immune structures along the tumor-immune border served as a hallmark of compartmentalization and were linked to survival.  We are currently working to build upon this initial effort to develop scoring mechanisms for guiding immune therapy drug selection.

    Learning Objectives:

    • Learn how MIBI technology enables simultaneous imaging of 40+ markers in FFPE tissue.
    • Learn how tumor expression and immune composition are interrelated with histological context that correlates with overall survival in TNBC

    Show Resources
    Loading Comments...